The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH CLL 2026 | Factors influencing the choice of continuous vs time-limited therapy in CLL
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses factors influencing the choice between continuous and time-limited therapy in chronic lymphocytic leukemia (CLL), including treatment convenience and the potential benefits of continuous BTK inhibitor therapy for patients with high-risk disease such as TP53 mutations or del(17p). This interview took place at the ESH CLL 2026 congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
For the continuous treatment, of course, the big advantage is for patients that it’s very easy to take. They don’t need the control due to potential tumor lysis syndrome with the ramp up with venetoclax. They don’t need infusions as for when you use the obinutuzumab in combination treatment. so it’s much more easy to take. And certainly for old or frail patients for whom it’s maybe sometimes even difficult to come to the doctor’s office for their appointment, this is a much easier type of treatment...
For the continuous treatment, of course, the big advantage is for patients that it’s very easy to take. They don’t need the control due to potential tumor lysis syndrome with the ramp up with venetoclax. They don’t need infusions as for when you use the obinutuzumab in combination treatment. so it’s much more easy to take. And certainly for old or frail patients for whom it’s maybe sometimes even difficult to come to the doctor’s office for their appointment, this is a much easier type of treatment. The other group which is probably benefiting or maybe benefiting more, at least with respect to the duration of the response, are patients with TP53 mutation or the deletion 17P, where at least for the duration of remission, it seems that the continuous treatment is more beneficial for those patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
